Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: Role for synaptic dopamine regulation in denervated nigrostriatal terminals

Tanya Chotibut, Victoria Fields, Michael F. Salvatore

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Pharmacological dopamine (DA) replacement with Levodopa [L-dihydroxyphenylalanine (L-DOPA)] is the gold standard treatment of Parkinson's disease (PD). However, long-term L-DOPA treatment is complicated by eventual debilitating abnormal involuntary movements termed L-DOPA-induced dyskinesia (LID), a clinically significant obstacle for themajority of patients who rely on L-DOPA to alleviate PD-related motor symptoms. The manifestation of LID may in part be driven by excessive extracellular DA derived from L-DOPA, but potential involvement of DA reuptake in LID severity or expression is unknown. We recently reported that in 6-hydroxydopamine (6-OHDA)-lesioned striatum, norepinephrine transporter (NET) expression increases and may play a significant role in DA transport. Furthermore, L-DOPA preferentially inhibits DA uptake in lesioned striatum. Therefore, we hypothesized that desipramine (DMI), a NET antagonist, could affect the severity of LID in an established LID model. Whereas DMI alone elicited no dyskinetic effects in lesioned rats, DMI + L-DOPA-treated rats gradually expressed more severe dyskinesia compared with L-DOPA alone over time. At the conclusion of the study, we observed reduced NET expression and norepinephrine-mediated inhibition of DA uptake in the DMI + L-DOPA group compared with L-DOPA-alone group in lesioned striatum. LID severity positively correlated with striatal extracellular signal-regulated protein kinase phosphorylation among the three treatment groups, with increased ppERK1/2 in DMI + L-DOPA group compared with the L-DOPA- and DMI-alone groups. Taken together, these results indicate that the combination of chronic L-DOPA and NET-mediated DA reuptake in lesioned nigrostriatal terminals may have a role in LID severity in experimental Parkinsonism.

Original languageEnglish
Pages (from-to)675-685
Number of pages11
JournalMolecular Pharmacology
Volume86
Issue number6
DOIs
StatePublished - 1 Dec 2014

Fingerprint Dive into the research topics of 'Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: Role for synaptic dopamine regulation in denervated nigrostriatal terminals'. Together they form a unique fingerprint.

  • Cite this